2017 IMPAACT Annual Meeting Treatment Scientific Committee Presentations

Welcome and Overview of Treatment Scientific Agenda

Maternal and Infant Health Outcomes in the Context of Universal Antiretroviral Treatment

Pharmacokinetics/Pharmacodynamics and Safety of ARVs During Pregnancy

Brookie Best

Pharmacokinetics/Pharmacodynamics and Safety of ARVs During Breastfeeding

Edmund Capparelli

IMPAACT 2010/VESTED: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants

P1026s: Pharmacokinetic Properties of Antiretroviral Therapy During Pregnancy

Mark Mirochnick

P1093: Phase I/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572 (Dolutegravir), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents

Ted Ruel

P1101: Phase I/II Dose-Finding, Safety, Tolerance, & PK Study of Raltegravir-Containing ART Regimen in HIV-Infected & TB Co-Infected Children

Tammy Meyers

P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants

Adrie Bekker

P1097: Raltegravir Pharmacokinetics and Safety in Neonates; and P1110: A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-Exposed Infants at High Risk

Diana Clarke

IMPAACT 2007: Phase I Safety & Pharmacokinetics of Maraviroc in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection

Ellen Chadwick

IMPAACT 2014: Phase I/II Trial of PK, Safety, & Tolerability of Doravirine & Doravirine/3TC/TDF in HIV-1-Infected Children & Adolescents

Ann Melvin

IMPAACT 2017: Phase I/II Study of Safety & PK of Oral & Long-acting Injectable Cabotegravir & Rilpivirine in Virologically Suppressed HIV-Infected Adolescents

Carolyn Bolton